About Us

Ondek was founded by Nobel Prize winner Dr Barry Marshall in 2005 to develop and commercialise a novel drug and vaccine delivery platform, based on the use of natural and genetically modified Helicobacter pylori bacteria.

Dr Marshall and his world renowned research team have developed a set of proprietary technologies, referred to as the Helicobacter pylori Platform Technology (HPPT). The HPPT has potential application for oral delivery of immunotherapies, biopharmaceuticals and other drugs, and vaccines.

Dr Marshall is a co-discoverer of the Helicobacter pylori organism and a co-recipient of the 2005 Nobel Prize for Medicine and Physiology as well as multiple other prestigious awards (including the 1995 Lasker Award) and elected a Fellow of the Royal Society in 1999. He is one of the most esteemed and pre-eminent biomedical scientists in the world today.